0
0
BOSTON — Researchers have long sought a “crystal ball” for asthma—a way to identify which patients are cruising toward a dangerous respiratory crisis and which are truly stable. Today, a landmark study published in Nature Communications suggests that the answer may lie not in the lungs, but in the blood.
In a collaborative effort between Mass General Brigham and Sweden’s Karolinska Institutet, scientists have developed a method to predict asthma exacerbations—commonly known as asthma attacks—with up to 90% accuracy, sometimes as far as five years before they occur. By analyzing the delicate balance of specific small molecules in the bloodstream, the team has opened a new door toward precision medicine for the more than 500 million people worldwide living with this chronic condition.
The Metabolic “Fingerprint” of an Attack
Asthma is notoriously unpredictable. While some patients manage their symptoms with daily maintenance inhalers, others suffer frequent, life-threatening “flares” that result in emergency room visits and long-term lung damage. Currently, doctors rely on a patient’s history of past attacks or basic lung function tests to guess future risk, but these methods are often imprecise.
To find a better way, researchers turned to metabolomics—the study of small molecules like sugars, amino acids, and fats created by the body’s metabolism.
Analyzing data from three large groups of participants totaling over 2,500 individuals, the team reviewed decades of electronic medical records. They discovered that the secret to prediction wasn’t just one single molecule, but the relationship between two specific classes: sphingolipids (fats involved in cell signaling and inflammation) and steroids (the body’s natural anti-inflammatories).
A Statistical Breakthrough: The Ratio Matters
The study found that while measuring individual levels of these molecules provided some clues, the sphingolipid-to-steroid ratio was the most powerful predictor of health.
“We found that the interaction between sphingolipids and steroids drives the risk profile,” explained Craig E. Wheelock, PhD, Principal Researcher at the Karolinska Institutet. “This ratio approach is not only biologically meaningful but also analytically robust, making it highly suitable for development into a practical, cost-effective clinical test.”
In practical terms, the model could differentiate the “time-to-first exacerbation” between high-risk and low-risk groups by nearly a full year. This means a doctor could potentially look at a patient’s blood work today and see a “red flag” for an attack that might not happen for months or even years, allowing for a preemptive change in treatment.
“Our findings solve a critical unmet need,” says Jessica Lasky-Su, ScD, Associate Professor at Mass General Brigham and Harvard Medical School. “By measuring this balance, we can identify high-risk patients with 90% accuracy, allowing clinicians to intervene before an attack occurs.”
The Shift to Precision Medicine
For the average person with asthma, this research signals a shift from “reactive” to “proactive” care. Currently, many patients only escalate their treatment after they start wheezing. If this blood test becomes standard, “stability” would no longer be defined by the absence of symptoms, but by a healthy metabolic balance.
What This Means for Patients:
-
Personalized Prevention: Patients who appear healthy but have a high-risk ratio might be prescribed stronger anti-inflammatory medications or more frequent check-ups.
-
Avoiding Over-Treatment: Conversely, patients with a low-risk ratio might eventually be able to reduce their medication dosages, minimizing side effects.
-
Objective Data: Like a cholesterol test for heart disease, this provides a “number” to track lung health over time.
The Road to the Doctor’s Office
While the results are groundbreaking, experts emphasize that this test isn’t available at your local clinic just yet. Independent experts note that while the 90% accuracy rate is impressive, the study must be replicated in more diverse populations.
“This is a sophisticated use of metabolomics that moves us closer to ‘personalized’ asthma care,” says Dr. Aris Papas, a pulmonologist not involved in the study. “However, we need to see how these ratios hold up in different ethnic groups and in patients with other co-existing conditions, like obesity or smoking history, which can also affect metabolic markers.”
Furthermore, the research team stresses that direct clinical trials and cost-effectiveness analyses are required before the test can be integrated into standard laboratory menus.
Public Health Implications
The stakes are high. Asthma exacerbations are a primary driver of healthcare costs and a leading cause of school and work absences. By identifying the 10-20% of patients who consume the majority of healthcare resources due to frequent attacks, the medical system could save billions while improving the quality of life for millions.
As the medical community moves toward “precision medicine”—tailoring treatment to an individual’s biology—this study provides a vital tool. It suggests that for the half-billion people fighting for breath, the future of treatment may be found in a simple vial of blood.
Reference Section
Peer-Reviewed Study:
-
Journal: Nature Communications (2026)
-
Title: “The ratio of circulatory levels of sphingolipids to steroids predicts asthma”
-
Authors: Yulu Chen, et al.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
